level of psychological distress may help prevent the development of the metabolic syndrome in women.
The secretory products of the pancreatic b cell have been identified not only as the major hormones regulating blood sugar, but also as potent neuropeptides influencing eating behavior and mood. 6 Moreover, type of insulin and route of application strongly influence the perception of hypoglycemia and emotionality. 7, 8 To investigate the association of psychological symptoms and intensively treated diabetes, we analyzed the psychological symptoms of depression and anxiety in patients receiving continuous insulin administration (CSII). In all, 52 type 1 diabetics (22 male, 30 female) at a mean age of 41.4 years and mean duration of diabetes mellitus of 20.9 years were enrolled in this study. Patients had been on insulin pumps for 3.870.89 years and reached a good level of glycemic control as documented by an HbA 1c value of 7.1670.89%. Anxiety and depression scores were analyzed using the Hospital Anxiety and Depression Score in its German version. 9 Patients on CSII presented with marked symptoms of both depression and anxiety. We found severe anxiety symptoms in 25% of our patients compared to 6.8% in the healthy cohort, while mild symptoms were less frequent (13.0 vs 20.2%), and the number of patients without symptoms was lower in the diabetic group (61.5 vs 73%). Depression scores showed an even more pronounced difference. Severe symptoms were found in 19.2% of the diabetic patients vs 0.7% in the healthy cohort. Mild depression was seen in 7.7 vs 4.3%.
To our knowledge, this is the first evaluation of psychological risk factors in a large cohort of Type 1 insulin-dependent patients on CSII. Significantly, higher anxiety and depression scores have been demonstrated in diabetic patients with postprandial hypoglycemia and enhanced insulin levels compared to controls. 10 Insulin-pen treatment has become widely established in recent years, and has improved subjective psychological tests in Type 1 diabetic patients compared to conventional syringes. 11 In our study, CSII did not prevent an increase in depression or anxiety in type 1 diabetic patients. This may be related to a long average duration of disease, high prevalence of complications (14 patients with retinopathy, nine with nephropathy, eight with neuropathy) and unchanged necessity for self-injections due to blood glucose self-monitoring, as well as adherence to diet. There was no significant correlation between the rate of hypoglycemia and increases in psychological stressors.
In the light of increased rate and aggravation of cardiovascular complications in patients with depression and diabetes, careful monitoring of psychological risk factors should be incorporated in disease management strategies for patients on CSII. presented evidence for a role in unipolar depression of the G1463A polymorphism in the 11th exon of the tryptophan hydroxylase 2 (TPH2) gene. Of special interest is their finding that seven of the nine unipolar depressed subjects carrying the rare 1463A allele were resistant to SSRI treatment. This association strongly suggested that this single-nucleotide polymorphism (SNP) is involved in major depression. We found no evidence of variation of the G1463A SNP via sequencing analysis in 182 patients with unipolar depression (of which 83 were treatment resistant), 186 nondepressed controls, and eight bipolar patients. We also report for the first time, the absence of nucleotide variation in a clinical population of two other SNPs in exon XI of the TPH2 gene (C1487G and T1578G).
The G1463A SNP results in an R441H amino-acid change in the TPH2 protein and has an 80% loss of function in serotonin production in PC12 cells. 1 Zhang et al (2005) investigated this SNP in a clinical population and found that the rare allele (A) frequency was 0.9% in controls (1AA, 2AG, 216GG) and 6.9% in patients with unipolar major depression (3AA, 6AG, 78GG). The striking difference in 1463A allele frequency between the unipolar depressed group and control subjects was highly suggestive of a role for this polymorphism or this genomic region in major depression. Furthermore, in the Zhang et al's 1 sample (N ¼ 306), the phenotype of seven of the nine unipolar depressed patients that carried the rare A allele were considered resistant to SSRI treatment, and the two remaining subjects were reportedly responsive to high SSRI doses. The high frequency of this rare allele and the endophenotype in which it was detected was highly suggestive of a role for TPH2 in treatment-resistant major depression. For this reason, we analyzed this SNP in 83 treatment-resistant unipolar depressed patients, eight treatment-resistant bipolar depressed patients, 99 nontreatment-resistant unipolar depressed patients and 186 control subjects without personal history of major affective disorders, using the same method described in Zhang et al Given the genotype frequencies in the previous study, we expected at least two AA and five AG genotypes in the treatment-resistant depression group alone, and at least six AA and 12 AG if the unipolar depression groups are combined (antidepressant responsive and resistant). Surprisingly, no variation at this locus was detected in any of the subjects. To confirm our gelbased genotyping findings, we sequenced all the samples for this genomic region and in so doing were able to analyze two other reported SNPs (see Table 1 ). One was reported in mouse models to result in a 40% decrease in the serotonin concentrations in both the frontal cortex and striatum of BALB/cJ mouse strains when compared to 129X1/SvJ mouse strains. 2 The corresponding position of this functional SNP in humans is P449R, resulting from a C1487G variation. A third SNP in this region is reported in dbSNP as rs7488262 and is a nonsynonymous change of T1578G and results in a D479E amino-acid change. 3 To the best of our knowledge, neither of these two SNPs has been reported in a clinical population to date.
Sequencing analysis of the G1463A SNP in the 83 treatment-resistant unipolar depressed patients, 99 nontreatment-resistant unipolar depressed patients, eight treatment-resistant bipolar depressed patients and 186 control subjects yielded no variation for any of the subject groups (all 376 GG). This is inconsistent with the genotype frequencies found in Zhang et al (2005) . Furthermore, sequencing analyses of C1487G and T1578G polymorphisms failed to provide evidence of the nucleotide variation in all of these subjects. In summary, although TPH2, and the variations within the TPH2 gene, may play a role in unipolar depression, at least in some patients identified by Zhang et al, our results do not provide supporting evidence for the involvement of exon XI polymorphisms in either treatment-resistant depression or unipolar major depression. a Nucleotide positions are determined from the 5 0 end of the TPH2 gene (no 5 0 -flanking region) ENSG00000139287; nucleotide position relative to the coordinate system. Superscripts indicate nucleotide position and correspond to nucleotide in Figure 1 in online supplemental materials.
